APP and Alzheimer disease: New GWAS have been developed with larger sample sizes, and several other risk loci have been identified and associated with AD, including TMEM106B, LILRB2, CCDC6, TNIP1, APP, TSPAN14, GRN, NCK2, SHARPIN [12,13], CST3, USP8, TGFB2 [14], RABEP1, PILRA, TP53INP1, AP4M1, SPI1, AP4E1, APBB3, ZYX [15], ACE, BCKDK/KAT8, ADAM10 [16], NTN5, HAVCR2, AGRN [13], LRRC25, FIBP, and KCNN4 [17], as well as enriched pathways such as endocytosis and the activation of microglia and macrophage [12,15,17].